Chinese big tech is dead, long live innovation

We're featured in the Belgian newspaper De Tijd, about big tech in China and the new dynamics in the sector, in China as well as in Europe.

Worg Pharmaceuticals to acquire Apitope International

  Agio Capital is happy and proud to have successfully supported another deal: the acquisition of Apitope by Worg Pharmaceuticals.

Article Reuters: Analysis: China's biotech sector comes of age with big licensing deals, global ambitions

Analysis: China's biotech sector comes of age with big licensing deals, global ambitions. We're the living proof of the growing impact of the Chinese life sciences and biotech market!

Biowin workshop: Everything you always wanted to know about Chinese investors but never dared to ask

Many events are happening the coming weeks, with the next Biowin – AGIO workshop being one of them. This online workshop is taking place September 30, from 10-12AM CET.

We're attending Knowledge for Growth 2021

We're attending Knowledge for Growth 2021, come meet us there September 28!

International Symposium on Treatment of Brain and Neurology Disorders

On October 5th, we're honored to co-organize with Industrial Technology Research Institute (ITRI)( 工業技術研究院 , 工研院 ) a CNS symposium in Taipei, Taiwan.

Biocentury Article: The mRNA therapeutics pipeline: Data Byte

mRNA technology is getting more and more attention, because of its use in COVID-19 vaccines, yet its use is more applicable than for COVID-19 only. Our client eTheRNA is one of the pioneering companies using this technology.

AGIO Capital & Business Solutions successfully supported Complix’s Global Drug Development License Deal with Chinese listed Jiangsu Nhwa Pharmaceutical Co.

Expanding Complix’s revolutionary Cell-Penetrating Alphabody platform beyond oncology & autoimmune diseases

Webinar: Update on Opportunities in China: Developing Your China Strategy

We are featured in a webinar hosted by our partner BioIndustry Association UK.

AGIO and Complix are featured in Mediaplanet's Life Sciences editorial

Every year, Mediaplanet publishes a Life Sciences editorial with interesting case studies, interviews and news happening in the life sciences sector. This year, AGIO is featured in there together with Complix, the company we recently helped signing a deal with the Chinese NASDAQ listed company I-Mab. 

Beijing has a plan, Brussels and Washington don't...

2020 was the year when the world noticed they had to watch out for China. For the first time, China received more foreign investments than the US. That is just the beginning of the increasing power China has been exercising.

China is taking the lead in times of Corona

Recently, we published an article in about how China is gaining strenght again after lockdown. China is taking the lead again, looking towards a bright future with focus on technology and innovation.

AGIO Capital assisted OMV Natie in the dealmaking process with Constructel

Agio Capital & Business Solutions and Agio Law assisted the Belgian telecom & utilities contractor OMV Natie in a transaction with Constructel/Visabeira.

Complix Signs Global Drug Discovery and Development Agreement with I-Mab

AGIO Capital & Business Solutions supported Complix in signing a global drug discovery and development agreement against two immuno-oncology intracellular targets, with Nasdaq listed I-Mab.

Agio Capital & Business Solutions successfully supported the Investment in UK listed company Futura Medical and Joint Collaboration for Greater China & South-East Asia

Supporting the investment and a 50:50 joint collaboration to commercialize MED3000 in Greater China & South-East Asia

FOKUS Business Guide: Blik op Azië

On February 15, 2021 Henk Joos, Roel Van Ranst and Philippe Van den Broecke were interviewed by FOKUS Business Guide about the relationship between AGIO Capital & Business Solutions and AGIO Law, and the position of Asia in the global business world.

AGIO joined BioIndustry Association

AGIO Capital & Business Solutions joins BioIndustry Association (BIA), the trade association for innovative life sciences in the UK.

Biovox article: A bridge from East to West: linking Chinese and European biotech

Our interview in the newsletter of BioVox (december 2020)

eTheRNA immunotherapies and China Grand Pharmaceutical set up AuroRNA

China Grand Pharmaceutical announced the successful set up of AuroRNA Biotech, a joint venture between eTheRNA immunotherapies and China Grand Pharmaceutical.

Agio Capital & Business Solutions successfully helped KLV LED Light Solutions

Agio Capital & Business Solutions supported KLV in reinforcing their team and shareholding

Agio Capital & Business Solutions successfully supported China partnership of Octimet Oncology

Octimet Oncology announces licensing deal with Shanghai Allist Pharmaceuticals for Greater China

A record-breaking year for investments in Belgian Biotech & Medtech companies

Proud to have supported 2 of the top 10 companies in capital raising

Agio Capital & Business Solutions successfully supported Miracor Medical

Supporting the € 24M financing round and contribution of Chinese capital

How China managed to control Corona

Our article from inside China about how China conquered Corona

Agio Capital & Business Solutions successfully supported eTheRNA immunotherapies

Supporting the € 34M Series B round of eTheRNA immunotherapies and the outline of a new strategic partnership

Coronavirus in China not only dangers, but also creates new opportunities

Agoria article by one of our Partners highlights opportunities in China during corona times

Cross-border strategies for China-EU Partnerships

Moderation on panel discussion by our director of life sciences & healthcare

Record number of Belgian companies at the China healthcare summit

Co-organization of Belgium Road Show Track at the China healthcare summit 2019

Belgian Princely Mission to China

Presenting the Belgian Life Sciences sector to Her Royal Highness Princess Astrid of Belgium

The growth of the Chinese pharma market, our interview in ‘De Tijd’

From 0 to the nr. 2 largest healthcare market globally, and here to stay

Your intellectual property in China

Reflections on our IP life sciences seminar with De Clercq & Partners

Dinner with the China Renaissance Delegation

A prestigious delegation of Chinese Pre-IPO Companies discovers the Belgian Life Sciences ecosystem

VOKA Mission to China

Presenting economic opportunities for Flemish companies in China

Let´s innovate together with China

In an interview with VOKA we highlight the need of cooperation with China

Partnership with Agoria

Agio Capital & Business Solutions signs partnership with Agoria, Belgium's biggest technology cluster organization

Doing biotech business in China: Risk or Big Opportunity?

Agio Capital & Business Solutions will lead the China Life Sciences workshop at knowledge for growth 2019, Europe's finest life sciences conference.

Agio Capital & Business Solutions successfully supported Promethera® Biosciences

Supporting the € 14.6M raise of convertible bonds of Promethera® Biosciences

Christmas concert 2018

Our Christmas Concert In the beautiful Sint-Anna chapel in Antwerp

Agio Capital & Business Solutions participates in panel discussion at China Healthcare Summit

Our Healthcare Director Henk Joos joined the expert panel discussion

Technology Festival Supernova 2018

Managing Partner David Haine presents cleantech opportunities in China

Barbecue for clients, partners and friends

A wonderful evening right in our office garden

2018: China VC has overtaken Silicon Valley

But do aggregate numbers tell the whole story?

Antwerp Forum: Linking business between China and Europe

Attending panel discussion about EU-China business cooperation